Oculis (NASDAQ:OCS) Shares Gap Up on Analyst Upgrade

Oculis Holding AG (NASDAQ:OCS)’s share price gapped up before the market opened on Friday after Stifel Nicolaus raised their price target on the stock from $35.00 to $40.00. The stock had previously closed at $19.48, but opened at $20.75. Stifel Nicolaus currently has a buy rating on the stock. Oculis shares last traded at $20.7950, with a volume of 43,282 shares changing hands.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Lifesci Capital started coverage on shares of Oculis in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of Oculis in a research report on Friday. They set an “overweight” rating and a $38.00 price objective on the stock. Finally, HC Wainwright boosted their price objective on Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Bosun Asset Management LLC acquired a new position in shares of Oculis during the second quarter worth about $378,000. Marshall Wace LLP purchased a new stake in shares of Oculis in the 2nd quarter worth about $393,000. Geode Capital Management LLC grew its position in shares of Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the last quarter. Bank of America Corp DE increased its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. Finally, Woodline Partners LP increased its position in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares in the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Stock Up 9.1%

The firm’s 50 day moving average is $20.10 and its 200-day moving average is $18.87. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.11 billion, a PE ratio of -8.43 and a beta of 0.32.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. As a group, equities research analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.